Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Jutte van derWerff ten Bosch"'
Autor:
Aniek Uittenboogaard, Marleen H. van denBerg, Floor C. H. Abbink, Jos W. R. Twisk, Inge M. van derSluis, Cor van denBos, Marry M. van denHeuvel‐Eibrink, Heidi Segers, Christophe Chantrain, Jutte van derWerff ten Bosch, Leen Willems, Gertjan J. L. Kaspers, Mirjam Esther van deVelde
Publikováno v:
Cancer Medicine, Vol 12, Iss 19, Pp 19480-19490 (2023)
AbstractIntroductionVincristine is an integral component of treatment for children with cancer. Its main dose‐limiting side effect is vincristine‐induced peripheral neuropathy (VIPN). The VINCA trial was a randomized controlled trial that explore
Externí odkaz:
https://doaj.org/article/876c15a1567543ef94a6d5f0460de85b
Autor:
Mirjam E. van deVelde, Marleen. H. van denBerg, Gertjan J. L. Kaspers, Floor C. H. Abbink, Jos W. R. Twisk, Inge M. van derSluis, Cor van denBos, Marry M. van denHeuvel‐Eibrink, Heidi Segers, Christophe Chantrain, Jutte van derWerff Ten Bosch, Leen Willems, Raphaële R. L. vanLitsenburg
Publikováno v:
Cancer Medicine, Vol 10, Iss 22, Pp 8172-8181 (2021)
Abstract Purpose Vincristine (VCR) is a chemotherapeutic agent used in the treatment of pediatric oncology patients, but its main toxicity is VCR‐induced peripheral neuropathy (VIPN). However, whether VIPN has an effect on health‐related quality
Externí odkaz:
https://doaj.org/article/e5e35beb568340dda7f7b38abc4d5585